Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Systems performance and glucose control using an advanced hybrid closed-loop system in type 1 diabetes: Insulin aspart vs. faster acting insulin aspart (FiASP)

Next Previous
Trial Profile

Systems performance and glucose control using an advanced hybrid closed-loop system in type 1 diabetes: Insulin aspart vs. faster acting insulin aspart (FiASP)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Medtronic; Novo Nordisk

Most Recent Events

  • 06 Aug 2021 Primary endpoint (Time spent with sensor glucose 3.910.0 mmol/L using uploaded CGM data) has been met as per results published in the Diabetes Care
  • 06 Aug 2021 Results published in the Diabetes Care
  • 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top